New therapies for acute kidney injury show promise

Acute kidney injury (AKI) is a severe renal disorder affecting approximately 10%-15% of hospitalized patients and up to 50% in intensive care units (ICUs). Its pathogenesis involves complex inflammatory regulatory mechanisms. As core components of the cytokine network, interleukins (ILs) exert pleiotropic effects in AKI development, extensively participating in inflammation, fibrosis, tissue injury repair, and remote organ damage.